INAB

SEC source: 0001415889-24-024867 · form4-10082024_041004.xml · derivative · entry 3

Brandt Peter C. · CIK 0001434099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 81,967 shares

Expires 2025-06-13

F3 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025.

F3 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025.

F5 · price: The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

F4 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001415889-24-024867 · form4-10082024_041004.xml · nonDerivative · entry 1

Brandt Peter C. · CIK 0001434099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 517,604

F1 · price: The reported securities are included within 253,164 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 253,164 shares of common stock.

SEC source: 0001415889-24-024872 · form4-10082024_041012.xml · derivative · entry 2

FAIRBAIRN EMILY · CIK 0001682638 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 3,038,743

Underlying: Common Stock · 3,038,743 shares

Expires not disclosed

F2 · price: The reported securities are included within 3,038,743 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share Pre-funded warrant and one Series C warrant each representing the right to purchase 3,038,743 shares of common stock.

F4 · derivative.exercise_date: The Pre-funded warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

F4 · derivative.expiration_date: The Pre-funded warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

F3 · ownership.nature: The securities are held by the Malcolm and Emily Charitable Remainder Unitrust 2010 (the "Trust"). The Reporting Person is the trustee of the Trust.

SEC source: 0001415889-24-024872 · form4-10082024_041012.xml · derivative · entry 1

FAIRBAIRN EMILY · CIK 0001682638 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 3,038,743

Underlying: Common Stock · 3,038,743 shares

Expires 2027-10-04

F2 · price: The reported securities are included within 3,038,743 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share Pre-funded warrant and one Series C warrant each representing the right to purchase 3,038,743 shares of common stock.

F1 · derivative.exercise_date: Fully vested and exercisable.

F3 · ownership.nature: The securities are held by the Malcolm and Emily Charitable Remainder Unitrust 2010 (the "Trust"). The Reporting Person is the trustee of the Trust.

SEC source: 0001415889-24-024866 · form4-10082024_041001.xml · derivative · entry 9

Ho William Tai-Wei · CIK 0001830914 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,582

Underlying: Common Stock · 126,582 shares

Expires 2027-10-04

F1 · price: The reported securities are included within 126,582 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 126,582 shares of common stock.

F4 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001415889-24-024866 · form4-10082024_041001.xml · derivative · entry 8

Ho William Tai-Wei · CIK 0001830914 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,967

Underlying: Common Stock · 81,967 shares

Expires 2025-10-04

F3 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025.

F3 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025.

F5 · price: The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

F4 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001415889-24-024866 · form4-10082024_041001.xml · derivative · entry 7

Ho William Tai-Wei · CIK 0001830914 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 81,967 shares

Expires 2025-06-13

F3 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025.

F3 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025.

F5 · price: The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

F4 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001415889-24-024866 · form4-10082024_041001.xml · nonDerivative · entry 1

Ho William Tai-Wei · CIK 0001830914 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,548,094

F1 · price: The reported securities are included within 126,582 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 126,582 shares of common stock.

SEC source: 0001104659-24-108140 · tm2425783-3_4seq1.xml · derivative · entry 11

Kreis Leslie W. · CIK 0001813316 · 10% owner

BIOS Fund III, LP · CIK 0001791917 · 10% owner

BIOS Fund III QP, LP · CIK 0001791916 · 10% owner

BIOS Fund III NT, LP · CIK 0001791910 · 10% owner

Bios Equity Partners II, LP · CIK 0001813313 · 10% owner

BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner

BP Directors, LP · CIK 0001813311 · 10% owner

Bios Equity Partners, LP · CIK 0001813314 · 10% owner

Cavu Management, LP · CIK 0001813270 · 10% owner

Cavu Advisors, LLC · CIK 0001813310 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 574,241

Underlying: Common Stock · 574,241 shares

Expires 2025-10-04

F2 · kind: In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024.

F2 · price: In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024.

F6 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF.

F7 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001104659-24-108140 · tm2425783-3_4seq1.xml · derivative · entry 10

Kreis Leslie W. · CIK 0001813316 · 10% owner

BIOS Fund III, LP · CIK 0001791917 · 10% owner

BIOS Fund III QP, LP · CIK 0001791916 · 10% owner

BIOS Fund III NT, LP · CIK 0001791910 · 10% owner

Bios Equity Partners II, LP · CIK 0001813313 · 10% owner

BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner

BP Directors, LP · CIK 0001813311 · 10% owner

Bios Equity Partners, LP · CIK 0001813314 · 10% owner

Cavu Management, LP · CIK 0001813270 · 10% owner

Cavu Advisors, LLC · CIK 0001813310 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 0

Underlying: Common Stock · 574,241 shares

Expires 2025-06-13

F2 · kind: In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024.

F2 · price: In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024.

F6 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF.

F7 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001104659-24-108140 · tm2425783-3_4seq1.xml · derivative · entry 9

Kreis Leslie W. · CIK 0001813316 · 10% owner

BIOS Fund III, LP · CIK 0001791917 · 10% owner

BIOS Fund III QP, LP · CIK 0001791916 · 10% owner

BIOS Fund III NT, LP · CIK 0001791910 · 10% owner

Bios Equity Partners II, LP · CIK 0001813313 · 10% owner

BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner

BP Directors, LP · CIK 0001813311 · 10% owner

Bios Equity Partners, LP · CIK 0001813314 · 10% owner

Cavu Management, LP · CIK 0001813270 · 10% owner

Cavu Advisors, LLC · CIK 0001813310 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 709,040

Underlying: Common Stock · 709,040 shares

Expires 2027-10-04

F1 · price: Pursuant to a Securities Purchase Agreement (the "Purchase Agreement"), dated as of September 30, 2024, between In8bio, Inc. (the "Issuer"), Bios Clinical Opportunity Fund, LP ("Bios COF Fund") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock and (ii) one Series C warrant (the "Series C Warrants") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F6 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF.

F7 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001104659-24-108140 · tm2425783-3_4seq1.xml · derivative · entry 8

Kreis Leslie W. · CIK 0001813316 · 10% owner

BIOS Fund III, LP · CIK 0001791917 · 10% owner

BIOS Fund III QP, LP · CIK 0001791916 · 10% owner

BIOS Fund III NT, LP · CIK 0001791910 · 10% owner

Bios Equity Partners II, LP · CIK 0001813313 · 10% owner

BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner

BP Directors, LP · CIK 0001813311 · 10% owner

Bios Equity Partners, LP · CIK 0001813314 · 10% owner

Cavu Management, LP · CIK 0001813270 · 10% owner

Cavu Advisors, LLC · CIK 0001813310 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 1,283,281

Underlying: Common Stock · 574,241 shares

Expires not disclosed

F1 · price: Pursuant to a Securities Purchase Agreement (the "Purchase Agreement"), dated as of September 30, 2024, between In8bio, Inc. (the "Issuer"), Bios Clinical Opportunity Fund, LP ("Bios COF Fund") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock and (ii) one Series C warrant (the "Series C Warrants") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F1 · derivative.exercise_date: Pursuant to a Securities Purchase Agreement (the "Purchase Agreement"), dated as of September 30, 2024, between In8bio, Inc. (the "Issuer"), Bios Clinical Opportunity Fund, LP ("Bios COF Fund") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock and (ii) one Series C warrant (the "Series C Warrants") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F1 · derivative.expiration_date: Pursuant to a Securities Purchase Agreement (the "Purchase Agreement"), dated as of September 30, 2024, between In8bio, Inc. (the "Issuer"), Bios Clinical Opportunity Fund, LP ("Bios COF Fund") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock and (ii) one Series C warrant (the "Series C Warrants") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F6 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF.

F7 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001104659-24-108139 · tm2425783-2_4seq1.xml · derivative · entry 11

Fletcher Aaron G.L. · CIK 0001789490 · 10% owner

BIOS Fund II, LP · CIK 0001714576 · 10% owner

BIOS Fund II QP, LP · CIK 0001716869 · 10% owner

BIOS Fund II NT, LP · CIK 0001728851 · 10% owner

BIOS Incysus Co-Invest I, LP · CIK 0001740029 · 10% owner

Bios Clinical Opportunity Fund, LP · CIK 0001988639 · 10% owner

Bios Equity COF, LP · CIK 0002000747 · 10% owner

BIOS Capital Management, LP · CIK 0001813845 · 10% owner

BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 574,241

Underlying: Common Stock · 574,241 shares

Expires 2025-10-04

F2 · kind: In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024.

F2 · price: In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024.

F6 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF.

F7 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001104659-24-108139 · tm2425783-2_4seq1.xml · derivative · entry 10

Fletcher Aaron G.L. · CIK 0001789490 · 10% owner

BIOS Fund II, LP · CIK 0001714576 · 10% owner

BIOS Fund II QP, LP · CIK 0001716869 · 10% owner

BIOS Fund II NT, LP · CIK 0001728851 · 10% owner

BIOS Incysus Co-Invest I, LP · CIK 0001740029 · 10% owner

Bios Clinical Opportunity Fund, LP · CIK 0001988639 · 10% owner

Bios Equity COF, LP · CIK 0002000747 · 10% owner

BIOS Capital Management, LP · CIK 0001813845 · 10% owner

BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 0

Underlying: Common Stock · 574,241 shares

Expires 2025-06-13

F2 · kind: In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024.

F2 · price: In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024.

F6 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF.

F7 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001104659-24-108139 · tm2425783-2_4seq1.xml · derivative · entry 9

Fletcher Aaron G.L. · CIK 0001789490 · 10% owner

BIOS Fund II, LP · CIK 0001714576 · 10% owner

BIOS Fund II QP, LP · CIK 0001716869 · 10% owner

BIOS Fund II NT, LP · CIK 0001728851 · 10% owner

BIOS Incysus Co-Invest I, LP · CIK 0001740029 · 10% owner

Bios Clinical Opportunity Fund, LP · CIK 0001988639 · 10% owner

Bios Equity COF, LP · CIK 0002000747 · 10% owner

BIOS Capital Management, LP · CIK 0001813845 · 10% owner

BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 709,040

Underlying: Common Stock · 709,040 shares

Expires 2027-10-04

F1 · price: Pursuant to a Securities Purchase Agreement (the "Purchase Agreement"), dated as of September 30, 2024, between In8bio, Inc. (the "Issuer"), Bios Clinical Opportunity Fund, LP ("Bios COF Fund") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock and (ii) one Series C warrant (the "Series C Warrants") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F6 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF.

F7 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001104659-24-108139 · tm2425783-2_4seq1.xml · derivative · entry 8

Fletcher Aaron G.L. · CIK 0001789490 · 10% owner

BIOS Fund II, LP · CIK 0001714576 · 10% owner

BIOS Fund II QP, LP · CIK 0001716869 · 10% owner

BIOS Fund II NT, LP · CIK 0001728851 · 10% owner

BIOS Incysus Co-Invest I, LP · CIK 0001740029 · 10% owner

Bios Clinical Opportunity Fund, LP · CIK 0001988639 · 10% owner

Bios Equity COF, LP · CIK 0002000747 · 10% owner

BIOS Capital Management, LP · CIK 0001813845 · 10% owner

BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 1,283,281

Underlying: Common Stock · 574,241 shares

Expires not disclosed

F1 · price: Pursuant to a Securities Purchase Agreement (the "Purchase Agreement"), dated as of September 30, 2024, between In8bio, Inc. (the "Issuer"), Bios Clinical Opportunity Fund, LP ("Bios COF Fund") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock and (ii) one Series C warrant (the "Series C Warrants") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F1 · derivative.exercise_date: Pursuant to a Securities Purchase Agreement (the "Purchase Agreement"), dated as of September 30, 2024, between In8bio, Inc. (the "Issuer"), Bios Clinical Opportunity Fund, LP ("Bios COF Fund") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock and (ii) one Series C warrant (the "Series C Warrants") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F1 · derivative.expiration_date: Pursuant to a Securities Purchase Agreement (the "Purchase Agreement"), dated as of September 30, 2024, between In8bio, Inc. (the "Issuer"), Bios Clinical Opportunity Fund, LP ("Bios COF Fund") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock and (ii) one Series C warrant (the "Series C Warrants") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F6 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF.

F7 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001415889-24-022927 · form4-09052024_040907.xml · derivative · entry 1

McCall Patrick · CIK 0001874384 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2034-09-04

F1 · derivative.exercise_date: Represents a retention award in the form of an option to purchase common stock. Twenty-five percent (25%) of the shares subject to the option shall vest on each of March 4, 2025 and September 4, 2025 and fifty percent (50%) of the shares subject to the option shall vest on March 4, 2026, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-24-022928 · form4-09052024_040909.xml · derivative · entry 1

Rochlin Kate · CIK 0001898521 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2034-09-04

F1 · derivative.exercise_date: Represents a retention award in the form of an option to purchase common stock. Twenty-five percent (25%) of the shares subject to the option shall vest on each of March 4, 2025 and September 4, 2025 and fifty percent (50%) of the shares subject to the option shall vest on March 4, 2026, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-24-022924 · form4-09052024_040901.xml · derivative · entry 1

Goswami Trishna · CIK 0001894243 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2034-09-04

F1 · derivative.exercise_date: Represents a retention award in the form of an option to purchase common stock. Twenty-five percent (25%) of the shares subject to the option shall vest on each of March 4, 2025 and September 4, 2025 and fifty percent (50%) of the shares subject to the option shall vest on March 4, 2026, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-24-022926 · form4-09052024_040905.xml · derivative · entry 1

Lamb Lawrence · CIK 0001830059 · EVP and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2034-09-04

F1 · derivative.exercise_date: Represents a retention award in the form of an option to purchase common stock. Twenty-five percent (25%) of the shares subject to the option shall vest on each of March 4, 2025 and September 4, 2025 and fifty percent (50%) of the shares subject to the option shall vest on March 4, 2026, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-24-022925 · form4-09052024_040903.xml · derivative · entry 1

Ho William Tai-Wei · CIK 0001830914 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2034-09-04

F1 · derivative.exercise_date: Represents a retention award in the form of an option to purchase common stock. Twenty-five percent (25%) of the shares subject to the option shall vest on each of March 4, 2025 and September 4, 2025 and fifty percent (50%) of the shares subject to the option shall vest on March 4, 2026, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-24-016969 · form4-06142024_050614.xml · derivative · entry 1

Greenwood Luba · CIK 0001853815 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,650

Underlying: Common Stock · 33,650 shares

Expires 2034-06-12

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 12, 2024; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-24-016964 · form4-06142024_050603.xml · derivative · entry 1

Roemer Alan S. · CIK 0001643070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,650

Underlying: Common Stock · 33,650 shares

Expires 2034-06-12

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 12, 2024; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-24-016965 · form4-06142024_050605.xml · derivative · entry 1

Brandt Peter C. · CIK 0001434099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,650

Underlying: Common Stock · 33,650 shares

Expires 2034-06-12

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 12, 2024; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-24-016967 · form4-06142024_050610.xml · derivative · entry 1

FAIRBAIRN EMILY · CIK 0001682638 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,650

Underlying: Common Stock · 33,650 shares

Expires 2034-06-12

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 12, 2024; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-24-016970 · form4-06142024_050616.xml · derivative · entry 1

Whitfill Travis · CIK 0001830178 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,650

Underlying: Common Stock · 33,650 shares

Expires 2034-06-12

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 12, 2024; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-24-016968 · form4-06142024_050612.xml · derivative · entry 1

Graff Jeremy R. · CIK 0001975028 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,650

Underlying: Common Stock · 33,650 shares

Expires 2034-06-12

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 12, 2024; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-24-016966 · form4-06142024_050607.xml · derivative · entry 1

Epperly Corinne · CIK 0001839156 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,650

Underlying: Common Stock · 33,650 shares

Expires 2034-06-12

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 12, 2024; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-24-003011 · form4-02082024_090253.xml · derivative · entry 1

McCall Patrick · CIK 0001874384 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 189,000

Underlying: Common Stock · 189,000 shares

Expires 2034-02-07

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on February 7, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-24-003017 · form4-02082024_090257.xml · derivative · entry 1

Rochlin Kate · CIK 0001898521 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,000

Underlying: Common Stock · 186,000 shares

Expires 2034-02-07

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on February 7, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-24-003019 · form4-02082024_090237.xml · derivative · entry 1

Goswami Trishna · CIK 0001894243 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,000

Underlying: Common Stock · 176,000 shares

Expires 2034-02-07

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on February 7, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-24-003025 · form4-02082024_090213.xml · derivative · entry 1

Epperly Corinne · CIK 0001839156 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2034-02-07

F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares subject to the option shall vest in equal monthly installments commencing on March 7, 2024, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-24-003023 · form4-02082024_090210.xml · derivative · entry 1

Ho William Tai-Wei · CIK 0001830914 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 502,000

Underlying: Common Stock · 502,000 shares

Expires 2034-02-07

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on February 7, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-24-003013 · form4-02082024_090230.xml · derivative · entry 1

Lamb Lawrence · CIK 0001830059 · EVP AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,000

Underlying: Common Stock · 169,000 shares

Expires 2034-02-07

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on February 7, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001104659-23-125826 · tm2332814-1_4seq1.xml · derivative · entry 10

Fletcher Aaron G.L. · CIK 0001789490 · 10% owner

BIOS Fund II, LP · CIK 0001714576 · 10% owner

BIOS Fund II QP, LP · CIK 0001716869 · 10% owner

BIOS Fund II NT, LP · CIK 0001728851 · 10% owner

BIOS Incysus Co-Invest I, LP · CIK 0001740029 · 10% owner

BIOS Fund III, LP · CIK 0001791917 · 10% owner

BIOS Fund III QP, LP · CIK 0001791916 · 10% owner

BIOS Fund III NT, LP · CIK 0001791910 · 10% owner

BIOS Capital Management, LP · CIK 0001813845 · 10% owner

BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 574,241

Underlying: Common Stock · 574,241 shares

Expires 2028-12-13

F1 · price: Pursuant to a Securities Purchase Agreement, dated as of December 11, 2023, between In8bio, Inc. (the "Issuer"), Bios Clinical Opportunity Fund, LP ("Bios COF Fund") and the other purchasers signatory thereto, Bios COF Fund purchased from the Issuer in a private placement 574,241 units at a price of $1.22 per unit, each unit consisting of (i) one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock, (ii) one Series A warrant to purchase one share of Common Stock and (iii) one Series B warrant to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F5 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF Fund. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF Fund. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors my be deemed to beneficially own the securities held directly by Bios COF Fund.

F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001104659-23-125826 · tm2332814-1_4seq1.xml · derivative · entry 9

Fletcher Aaron G.L. · CIK 0001789490 · 10% owner

BIOS Fund II, LP · CIK 0001714576 · 10% owner

BIOS Fund II QP, LP · CIK 0001716869 · 10% owner

BIOS Fund II NT, LP · CIK 0001728851 · 10% owner

BIOS Incysus Co-Invest I, LP · CIK 0001740029 · 10% owner

BIOS Fund III, LP · CIK 0001791917 · 10% owner

BIOS Fund III QP, LP · CIK 0001791916 · 10% owner

BIOS Fund III NT, LP · CIK 0001791910 · 10% owner

BIOS Capital Management, LP · CIK 0001813845 · 10% owner

BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 574,241

Underlying: Common Stock · 574,241 shares

Expires 2025-06-13

F1 · price: Pursuant to a Securities Purchase Agreement, dated as of December 11, 2023, between In8bio, Inc. (the "Issuer"), Bios Clinical Opportunity Fund, LP ("Bios COF Fund") and the other purchasers signatory thereto, Bios COF Fund purchased from the Issuer in a private placement 574,241 units at a price of $1.22 per unit, each unit consisting of (i) one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock, (ii) one Series A warrant to purchase one share of Common Stock and (iii) one Series B warrant to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F5 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF Fund. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF Fund. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors my be deemed to beneficially own the securities held directly by Bios COF Fund.

F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001104659-23-125826 · tm2332814-1_4seq1.xml · derivative · entry 8

Fletcher Aaron G.L. · CIK 0001789490 · 10% owner

BIOS Fund II, LP · CIK 0001714576 · 10% owner

BIOS Fund II QP, LP · CIK 0001716869 · 10% owner

BIOS Fund II NT, LP · CIK 0001728851 · 10% owner

BIOS Incysus Co-Invest I, LP · CIK 0001740029 · 10% owner

BIOS Fund III, LP · CIK 0001791917 · 10% owner

BIOS Fund III QP, LP · CIK 0001791916 · 10% owner

BIOS Fund III NT, LP · CIK 0001791910 · 10% owner

BIOS Capital Management, LP · CIK 0001813845 · 10% owner

BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 574,241

Underlying: Common Stock · 574,241 shares

Expires not disclosed

F1 · price: Pursuant to a Securities Purchase Agreement, dated as of December 11, 2023, between In8bio, Inc. (the "Issuer"), Bios Clinical Opportunity Fund, LP ("Bios COF Fund") and the other purchasers signatory thereto, Bios COF Fund purchased from the Issuer in a private placement 574,241 units at a price of $1.22 per unit, each unit consisting of (i) one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock, (ii) one Series A warrant to purchase one share of Common Stock and (iii) one Series B warrant to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F1 · derivative.expiration_date: Pursuant to a Securities Purchase Agreement, dated as of December 11, 2023, between In8bio, Inc. (the "Issuer"), Bios Clinical Opportunity Fund, LP ("Bios COF Fund") and the other purchasers signatory thereto, Bios COF Fund purchased from the Issuer in a private placement 574,241 units at a price of $1.22 per unit, each unit consisting of (i) one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock, (ii) one Series A warrant to purchase one share of Common Stock and (iii) one Series B warrant to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F5 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF Fund. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF Fund. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors my be deemed to beneficially own the securities held directly by Bios COF Fund.

F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001104659-23-125830 · tm2332814-2_4seq1.xml · derivative · entry 10

Kreis Leslie W. · CIK 0001813316 · 10% owner

Bios Equity Partners II, LP · CIK 0001813313 · 10% owner

BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner

BP Directors, LP · CIK 0001813311 · 10% owner

Bios Equity Partners, LP · CIK 0001813314 · 10% owner

Cavu Management, LP · CIK 0001813270 · 10% owner

Cavu Advisors, LLC · CIK 0001813310 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 574,241

Underlying: Common Stock · 574,241 shares

Expires 2028-12-13

F1 · price: Pursuant to a Securities Purchase Agreement, dated as of December 11, 2023, between In8bio, Inc. (the "Issuer"), Bios Clinical Opportunity Fund, LP ("Bios COF Fund") and the other purchasers signatory thereto, Bios COF Fund purchased from the Issuer in a private placement 574,241 units at a price of $1.22 per unit, each unit consisting of (i) one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock, (ii) one Series A warrant to purchase one share of Common Stock and (iii) one Series B warrant to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F5 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF Fund. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF Fund. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors my be deemed to beneficially own the securities held directly by Bios COF Fund.

F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001104659-23-125830 · tm2332814-2_4seq1.xml · derivative · entry 9

Kreis Leslie W. · CIK 0001813316 · 10% owner

Bios Equity Partners II, LP · CIK 0001813313 · 10% owner

BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner

BP Directors, LP · CIK 0001813311 · 10% owner

Bios Equity Partners, LP · CIK 0001813314 · 10% owner

Cavu Management, LP · CIK 0001813270 · 10% owner

Cavu Advisors, LLC · CIK 0001813310 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 574,241

Underlying: Common Stock · 574,241 shares

Expires 2025-06-13

F1 · price: Pursuant to a Securities Purchase Agreement, dated as of December 11, 2023, between In8bio, Inc. (the "Issuer"), Bios Clinical Opportunity Fund, LP ("Bios COF Fund") and the other purchasers signatory thereto, Bios COF Fund purchased from the Issuer in a private placement 574,241 units at a price of $1.22 per unit, each unit consisting of (i) one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock, (ii) one Series A warrant to purchase one share of Common Stock and (iii) one Series B warrant to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F5 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF Fund. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF Fund. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors my be deemed to beneficially own the securities held directly by Bios COF Fund.

F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001104659-23-125830 · tm2332814-2_4seq1.xml · derivative · entry 8

Kreis Leslie W. · CIK 0001813316 · 10% owner

Bios Equity Partners II, LP · CIK 0001813313 · 10% owner

BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner

BP Directors, LP · CIK 0001813311 · 10% owner

Bios Equity Partners, LP · CIK 0001813314 · 10% owner

Cavu Management, LP · CIK 0001813270 · 10% owner

Cavu Advisors, LLC · CIK 0001813310 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 574,241

Underlying: Common Stock · 574,241 shares

Expires not disclosed

F1 · price: Pursuant to a Securities Purchase Agreement, dated as of December 11, 2023, between In8bio, Inc. (the "Issuer"), Bios Clinical Opportunity Fund, LP ("Bios COF Fund") and the other purchasers signatory thereto, Bios COF Fund purchased from the Issuer in a private placement 574,241 units at a price of $1.22 per unit, each unit consisting of (i) one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock, (ii) one Series A warrant to purchase one share of Common Stock and (iii) one Series B warrant to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F1 · derivative.expiration_date: Pursuant to a Securities Purchase Agreement, dated as of December 11, 2023, between In8bio, Inc. (the "Issuer"), Bios Clinical Opportunity Fund, LP ("Bios COF Fund") and the other purchasers signatory thereto, Bios COF Fund purchased from the Issuer in a private placement 574,241 units at a price of $1.22 per unit, each unit consisting of (i) one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock, (ii) one Series A warrant to purchase one share of Common Stock and (iii) one Series B warrant to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F5 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF Fund. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF Fund. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors my be deemed to beneficially own the securities held directly by Bios COF Fund.

F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001209191-23-058717 · doc4.xml · derivative · entry 3

McCall Patrick · CIK 0001874384 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,492

Underlying: Common Stock · 20,492 shares

Expires 2028-12-13

F1 · price: The reported securities are included within 20,492 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 20,492 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001209191-23-058717 · doc4.xml · derivative · entry 2

McCall Patrick · CIK 0001874384 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,492

Underlying: Common Stock · 20,492 shares

Expires 2025-06-13

F1 · price: The reported securities are included within 20,492 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 20,492 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001209191-23-058717 · doc4.xml · nonDerivative · entry 1

McCall Patrick · CIK 0001874384 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,755

F1 · price: The reported securities are included within 20,492 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 20,492 shares of common stock.

SEC source: 0001209191-23-058716 · doc4.xml · derivative · entry 3

Rochlin Kate · CIK 0001898521 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,295

Underlying: Common Stock · 12,295 shares

Expires 2028-12-13

F1 · price: The reported securities are included within 12,295 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 12,295 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001209191-23-058716 · doc4.xml · derivative · entry 2

Rochlin Kate · CIK 0001898521 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,295

Underlying: Common Stock · 12,295 shares

Expires 2025-06-13

F1 · price: The reported securities are included within 12,295 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 12,295 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001209191-23-058716 · doc4.xml · nonDerivative · entry 1

Rochlin Kate · CIK 0001898521 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,558

F1 · price: The reported securities are included within 12,295 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 12,295 shares of common stock.

SEC source: 0001209191-23-058715 · doc4.xml · derivative · entry 3

Goswami Trishna · CIK 0001894243 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,098

Underlying: Common Stock · 4,098 shares

Expires 2028-12-13

F1 · price: The reported securities are included within 4,098 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 4,098 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001209191-23-058715 · doc4.xml · derivative · entry 2

Goswami Trishna · CIK 0001894243 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,098

Underlying: Common Stock · 4,098 shares

Expires 2025-06-13

F1 · price: The reported securities are included within 4,098 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 4,098 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001209191-23-058715 · doc4.xml · nonDerivative · entry 1

Goswami Trishna · CIK 0001894243 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,729

F1 · price: The reported securities are included within 4,098 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 4,098 shares of common stock.

SEC source: 0001209191-23-058719 · doc4.xml · derivative · entry 3

Roemer Alan S. · CIK 0001643070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,459

Underlying: Common Stock · 102,459 shares

Expires 2028-12-13

F1 · price: The reported securities are included within 102,459 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 102,459 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.